ARGENX SE

Argenx’s FcRn‑targeted biologic Vyvgart offers a precision approach to autoimmune disease, spotlighting its market potential, regulatory hurdles, and competitive edge.

Argenx & Halozyme reshape advanced therapeutics: high‑margin biologics meet delivery tech, boosting value‑based pricing and investor confidence.

Argenx’s AI‑powered portfolio tools at Exchange26 EMEA show 10 pp gains in success rates and €27 M ROI, while Sanofi’s Phase III withdrawal warns of high clinical‑risk costs.

Argenx’s June 2026 investor events highlight its FcRn‑blocker efgartigimod, detailing clinical progress, pricing strategy, and a $310 M revenue outlook for severe autoimmune therapy.

Janus Henderson’s Global Sustainable Equity Active ETF outperformed MSCI World in April 2026 by leveraging AI‑driven tech gains, underweighting weak energy and staples, and positioning for long‑term renewable growth.

Argenx SE’s earnings prompt revised analyst targets amid leadership shifts: solid 12% revenue growth, 28% margin, €115m cash flow, yet cautious valuations reflect market uncertainty yet strong pipeline optimism.

FDA approves Argenx’s Vyvgart for CIDP, expanding its neuro‑immune reach and unlocking a $1B+ market with proven efficacy and a solid safety profile.

Argenx’s expanded FDA approval of efgartigimod (VYVGART) for all adult generalized myasthenia gravis patients—irrespective of serotype—offers a broader, serotype‑agnostic treatment option, backed by Phase 3 data showing rapid, sustained symptom impr…

FDA expands VYVGART label to all adult generalized myasthenia gravis patients—evidence shows significant, sustained benefit across all serotypes, simplifying treatment and improving access.

Argenx SE’s share price jumped 12 % in the last year thanks to a strong antibody pipeline, growing revenue and better margins, but regulatory delays, clinical risk, and competition may temper this rally.